Modelling and Verification of Timed Robotic Controllers

Designing robotic systems can be very challenging, yet controllers are often specified using informal notations with development driven primarily by simulations and physical experiments, without relation to abstract models of requirements. The ability to perform formal analysis and replicate results across different robotic platforms is hindered by the lack of well-defined formal notations. In this paper we present a timed state-machine based formal notation for robotics that is informed by current practice. We motivate our work with an example from swarm robotics and define a compositional CSP-based discrete timed semantics suitable for refinement. Our results support verification and, importantly, enable rigorous connection with sound simulations and deployments.</p

BIBDB: A Bibliographic Database for Collaboration

While researchers strive to develop new systems to enhance the cooperative document editing process, many authors already collaborate, using existing text processing systems to produce papers and reports. Using these tools, one of the most time-consuming and error-prone collaboration tasks is maintaining a consistent shared bibliography. We have designed and implemented the BIBDB system to simplify collaborative authoring by providing a shared, cooperatively maintained bibliographicdatabase. BIBDB uses existing networkingtechnology and merges seamlessly into the LAT E X/BIBT E X text processing system [5]. The contributions of BIBDB include a set of user interface policies and software implementation techniques that support cooperative database maintenance

Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia

To evaluate the lipid-altering efficacy and safety of ezetimibe monotherapy in young children with heterozygous familial hypercholesterolemia (HeFH) or nonfamilial hypercholesterolemia (nonFH). One hundred thirty-eight children 6-10 years of age with diagnosed HeFH or clinically important nonFH (low-density lipoprotein cholesterol [LDL-C] ≥ 160 mg/dL [4.1 mmol/L]) were enrolled into a multicenter, 12-week, randomized, double-blind, placebo-controlled study. Following screening/drug washout and a 5-week single-blind placebo-run-in with diet stabilization, subjects were randomized 2:1 to daily ezetimibe 10 mg (n = 93) or placebo (n = 45) for 12 weeks. Lipid-altering efficacy and safety were assessed in all treated patients. Overall, mean age was 8.3 years, 57% were girls, 80% were white, mean baseline LDL-C was 228 mg/dL (5.9 mmol/L), and 91% had HeFH. After 12 weeks, ezetimibe significantly reduced LDL-C by 27% after adjustment for placebo (P < .001) and produced significant reductions in total cholesterol (21%), nonhigh-density lipoprotein cholesterol (26%), and apolipoprotein B (20%) (P < .001 for all). LDL-C lowering response in sex, race, baseline lipids, and HeFH/nonFH subgroups was generally consistent with overall study results. Ezetimibe was well tolerated, with a safety profile similar to studies in older children, adolescents, and adults. Ezetimibe monotherapy produced clinically relevant reductions in LDL-C and other key lipid variables in young children with primary HeFH or clinically important nonFH, with a favorable safety/tolerability profile. ClinicalTrials.gov: NCT0086716

Accounting for age of onset and family history improves power in genome-wide association studies

Genome-wide association studies (GWASs) have revolutionized human genetics, allowing researchers to identify thousands of disease-related genes and possible drug targets. However, case-control status does not account for the fact that not all controls may have lived through their period of risk for the disorder of interest. This can be quantified by examining the age-of-onset distribution and the age of the controls or the age of onset for cases. The age-of-onset distribution may also depend on information such as sex and birth year. In addition, family history is not routinely included in the assessment of control status. Here, we present LT-FH++, an extension of the liability threshold model conditioned on family history (LT-FH), which jointly accounts for age of onset and sex as well as family history. Using simulations, we show that, when family history and the age-of-onset distribution are available, the proposed approach yields statistically significant power gains over LT-FH and large power gains over genome-wide association study by proxy (GWAX). We applied our method to four psychiatric disorders available in the iPSYCH data and to mortality in the UK Biobank and found 20 genome-wide significant associations with LT-FH++, compared to ten for LT-FH and eight for a standard case-control GWAS. As more genetic data with linked electronic health records become available to researchers, we expect methods that account for additional health information, such as LT-FH++, to become even more beneficial